3 High-Potential Stocks to Buy at Rock-Bottom Prices


  • These companies hold opportunities for substantial gains backed by a solid operational edge and related fundamentals.
  • Celestica (CLS): Has demonstrated commendable performance, warked by significant top-line growth, margin expansion, and profitability improvements.
  • AdaptHealth (AHCO): Achieves resilience through effective cash flow management and progress in deleveraging despite challenges.
  • Teladoc Health (TDOC): Delivers stable growth in chronic care enrollment, indicating compelling offerings and recurring revenue opportunities.
Cheap Stocks with High Potential - 3 High-Potential Stocks to Buy at Rock-Bottom Prices

Source: Shutterstock

Finding investing opportunities in the market might be challenging. Nevertheless, three equities stick out due to their ability to yield large profits during volatility. The first one sticks out due to its strong financial performance, which is characterized by considerable sales, margins, and profitability increases. The company’s growth trajectory and durability against market uncertainty make it a desirable investment for those looking for stability and upside potential in the electronic manufacturing services industry.

Moreover, the second one exhibits tenacity in the face of difficulties. It showcases skillful cash flow management and advancements in deleveraging initiatives. Even though the company has encountered challenges, it can control risks and uphold financial discipline. This highlights its growth potential and offers investors interested in the healthcare distribution industry a compelling opportunity.

Finally, the third one shows encouraging growth potential in the healthcare technology sector. A consistent increase in chronic care enrollment fuels this. The pattern indicates long-term income potential as well as the efficacy of the company’s solutions, making it a desirable option for investors hoping to profit from the growing virtual care market.

Celestica (CLS)

Person holding cellphone with website of Canadian electronics company Celestica Inc. (CLS) on screen in front of logo. Focus on center of phone display. Unmodified photo.
Source: T. Schneider / Shutterstock.com

Celestica’s (NYSE:CLS) first-quarter 2024 revenue of $2.21 billion had a solid 20% boost. This is over the company’s $1.84 billion revenue during the same period in 2023. The Communications, Consumer, and Enterprise (CCS) segment has a solid performance, reporting an impressive 38% year-over-year (YoY) increase. It was the main driver of the company’s top-line gain. Moreover, the revenue increase indicates Celestica’s capacity to seize market openings and satisfy client demand, especially in areas like AI/ML computing solutions and hyperscale clients.

Additionally, the Advanced Technology Solutions (ATS) division has a 4.7% segment margin in the first quarter of 2024. This is up from 4.4% at the same time in 2023, despite a minor 3% fall in sales YoY. Notably, the ATS segment’s Aerospace and Defense (A&D) division demonstrated a robust double-digit revenue increase YoY, highlighting the segment’s durability and development potential.

Overall, Celestica’s revenue from its capital equipment sector saw a little increase and stabilization compared to last year’s quarter, suggesting a rebound and an optimistic market attitude in this particular category.

Adapthealth (AHCO)

Medicine and healthcare concept - team or group of doctors and nurses
Source: Supavadee butradee / Shutterstock.com

Even with adversities like payments being delayed due to the Change Healthcare data breach, Adapthealth (NASDAQ:AHCO) could still produce $49 million in operating cash flow (Q1 2024). Even though this is less than the $140.2 million from Q1 2023, it nevertheless signifies Adapthealth’s resiliency in managing cash flow against operation adversities. Despite obstacles, AdaptHealth’s free cash flow projection for H1 2024 is unchanged. The company is projecting a free cash flow of at least $55 million. In short, the company has the fundamental capacity to deal with sporadic setbacks and preserve its stability.

Additionally, using a deleveraging strategy, the company has sharply lowered its consolidated debt levels and leverage ratios during the last 12 months. AdaptHealth executed a disciplined approach to debt reduction by continuing to pay down debt over minimum payments during the Change in Healthcare difficulties.

Finally, AdaptHealth reduced from 3.16 times at the end of 2023 to 3.12 times at the end of Q1 2024, with $25 million going toward debt repayment in Q1 2024 and an additional $15 million after the quarter’s end. Therefore, these efforts to pay down debt are ongoing, strengthening its financial standing and lowering risk.

Teladoc  (TDOC)

The Teladoc logo through a magnifying glass.
Source: Postmodern Studio / Shutterstock.com

Enrollment in chronic care at Teladoc (NYSE:TDOC) increased by a solid 9% YoY. At the end of the first quarter of 2024, there were $1.12 million members enrolled. This expansion shows a growing need for Teladoc’s chronic care solutions, which is good news for the company’s product line and clientele. Thus, Teladoc’s stable increase in chronic care membership strengthens long-term profitability and recurring revenue streams.

Moreover, Teladoc uses AI and data to improve client interaction and drive efficiency throughout its business processes. The organization uses AI models in provider matching, enrollment optimization, and member engagement, among other areas of its operations. AI makes personalized consumer interactions easier, enhancing service delivery and boosting income.

Finally, Teladoc has successfully implemented a land and grow strategy, as seen by the roughly 2.2 million new members who have joined during the last quarter. The company’s primary strategy is cross-selling to current customers; cross-selling accounted for two-thirds of all bookings in the first quarter. Therefore, future cross-selling and product penetration have a lot of potential, thanks to Teladoc’s growing membership base.

On the date of publication, Yiannis Zourmpanos did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Yiannis Zourmpanos is the founder of Yiazou Capital Research, a stock-market research platform designed to elevate the due diligence process through in-depth business analysis.

Article printed from InvestorPlace Media, https://investorplace.com/2024/05/3-high-potential-stocks-to-buy-at-rock-bottom-prices/.

©2024 InvestorPlace Media, LLC